Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.32 |
| ▸ | ITGAV | P06756 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.32 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | CAD | P27708 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7271734 | 1.00 | HTT (0.38) | HTTSMN1; SMN2ITGB3ITGB2ITGB1 | |
| SCHEMBL21176305 | 0.84 | MEN1 (0.37) | HTTKDM4ECYP2C19MAPT | |
| SCHEMBL21183544 | 0.79 | KMT2A (0.42) | HTTSMN1; SMN2KDM4EMAPT | |
| SCHEMBL27952230 | 0.71 | HTT (0.35) | HTT | |
| SCHEMBL11763607 | 0.71 | HTT (0.42) | HTT | |
| SCHEMBL7334907 | 0.71 | CAD (0.32) | CAD | |
| SCHEMBL16097822 | 0.70 | — | — | |
| SCHEMBL10345486 | 0.67 | HTT (0.41) | HTTAPLNR | |
| SCHEMBL10345485 | 0.67 | HTT (0.41) | HTTAPLNR | |
| SCHEMBL29555621 | 0.67 | HTT (0.32) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009074518-A1 | COMBINATIONS OF PROLINAMIDE P2X7 MODULATORS WITH FURTHER THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| EP-2049478-A1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | Glaxo Group Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008003697-A1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | WO | disclosed |
| EP-0473993-B1 | Novel peptide derivatives and their pharmaceutical use | JAPAN TOBACCO INC (JP) | 1996-04-17 | — | — | EP | disclosed |
| US-5151497-A | Central nervous system disorders, antidepressants, epilepsy and cognition activators | JAPAN TOBACCO INC. (JP) | 1992-09-29 | — | — | US | disclosed |
| EP-0473993-A2 | Novel peptide derivatives and their pharmaceutical use | Japan Tobacco Inc. (JP) | 1992-03-11 | — | — | EP | disclosed |